Systemic Antifungal Therapy Combined With Q-Switched Nd:YAG Laser Versus Systemic Antifungal Therapy Alone in the Treatment of Onychomycosis
Sponsor study identifier
interventional
97
0 countries
N/A
Study Start
October 10, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
October 10, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
February 10, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
This randomized controlled trial aims to compare the efficacy and safety of systemic terbinafine combined with Q-switched Nd:YAG laser versus systemic terbinafine alone in the treatment of onychomycosis.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
February 10, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 6, 2026
Actual (reported)October 9, 2026
Actual (reported)October 10, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
October 10, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
February 10, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Change in Onychomycosis Severity Index
Mean change in Onychomycosis Severity Index (OSI) score (range 0 to 35, higher scores indicate more severe disease) from baseline to end of treatment.
At 3 months
Mycological cure rate
At 3 months
Clinical cure rate
At 3 months
Patient satisfaction score
At 3 months
Number of patients with treatment-related adverse events
At 3 months
Oral terbinafine 250 mg daily plus Q-switched Nd:YAG laser sessions every 2 weeks for 6 sessions.
Oral terbinafine 250 mg daily without laser therapy.
Oral terbinafine 250 mg once daily for 6 weeks (fingernails) or 12 weeks (toenails).
Q-switched Nd:YAG laser (1064 nm) applied to the affected nail plate, 4 passes per session, every 2 weeks for 6 sessions.
Sahar A Ahmed, prof
Dermatology Department, Assiut University Hospitals
First Submitted
October 6, 2026
First Posted
October 9, 2026
Study Start
October 10, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
October 10, 2027
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
February 10, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
October 9, 2026
Record last verified: 2026-10
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: